COR 001 - Corvidia Therapeutics

Drug Profile

COR 001 - Corvidia Therapeutics

Alternative Names: COR-001

Latest Information Update: 27 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer Corvidia Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cardiovascular disorders

Most Recent Events

  • 05 Apr 2017 University of Colorado and Corvidia Therapeutics initiate enrolment in a phase I pharmacokinetic and pharmacodynamic trial in patients with Renal failure and Inflammation in USA (NCT03126318)
  • 23 Aug 2016 Discontinued - Phase-I for Anaemia before February 2016
  • 16 Aug 2016 Phase-I/II clinical trials in Anaemia in USA (SC) (NCT02868229)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top